Lupus & antiphospholipid syndrome
V‐Set Immunoglobulin Domain–Containing Protein 4 as a Novel Serum Biomarker of Lupus Nephritis and Renal Pathology Activity
Authors' conclusion
VSIG4 may be a promising novel serum biomarker and therapeutic target in patients with LN.
Study context
- Population
- Patients with lupus nephritis (LN), disease controls with other CKD, and healthy controls
- Participants
- 155 final validation serum samples
- Comparison
- Serum proteins in LN vs healthy controls and other chronic kidney diseases
- Outcome
- Novel serum biomarkers with diagnostic or predictive value in LN
Methodological detailsquantitative protein microarray screening, ELISA validation, machine-learning feature selection, multi-stage validation cohorts
- Quantitative protein microarray screening
- ELISA validation
- Machine-learning feature selection
- Multi-stage validation cohorts
Performance
As reported in the abstract
VSIG4 distinguishing LN from healthy controls
| Test or model | AUC |
|---|---|
| LN | 0.93 |
LN
AUC0.93
- Proteins validated by ELISA (81 serum samples)
- 8
- Serum markers with LN diagnostic potential identified by feature importance analysis
- 3
Further findings
Correlation of serum VSIG4 with clinical parameters (Spearman rs)
- Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, rs
- 0.42 (P < 0.001)
- Renal domain score of SLEDAI, rs
- 0.46 (P < 0.001)
- Urinary protein-to-creatinine ratio, rs
- 0.56 (P < 0.001)
- Serum creatinine, rs
- 0.41 (P < 0.001)
Longitudinal tracking and renal pathology
- Serum VSIG4 tracked with LN disease activity longitudinally
- Serum VSIG4 reflected renal pathology activity index (AI), particularly crescent formation and hyaline deposits
Original publication
V‐Set Immunoglobulin Domain–Containing Protein 4 as a Novel Serum Biomarker of Lupus Nephritis and Renal Pathology Activity. Arthritis Rheumatol. Published 4 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →